Baseline characteristics of patients in epcoritamab vs SOC/CIT cohorts
| Characteristic . | Unadjusted epcoritamab FL, % (n = 128) . | Adjusted epcoritamab FL, % (ESS = 44) . | Pooled SCHOLAR-5, % (n = 206) . |
|---|---|---|---|
| Age ≥65 years | 52.3 | 53.5 | 53.5 |
| Male | 61.7 | 58.4 | 58.4 |
| ECOG PS 0 (vs 1-2) | 54.7 | 36.6 | 36.6 |
| Disease stage III-IV | 85.2 | 85.4 | 85.4 |
| FLIPI score of ≥3 | 60.9 | 35.4 | 35.4 |
| Prior CAR T therapy | 4.7 | 0.0 | 0.0 |
| Prior ASCT | 18.8 | 20.1 | 20.1 |
| POD24 | 52.3 | 26.8 | 26.8 |
| Refractory to last prior therapy | 68.8 | 46.4 | 46.4 |
| ≥3 prior LOTs (vs <3) | 63.3 | 57.6 | 57.6 |
| Bulky disease (>7 cm) | 11.7 | 22.1 | 22.1 |
| Characteristic . | Unadjusted epcoritamab FL, % (n = 128) . | Adjusted epcoritamab FL, % (ESS = 44) . | Pooled SCHOLAR-5, % (n = 206) . |
|---|---|---|---|
| Age ≥65 years | 52.3 | 53.5 | 53.5 |
| Male | 61.7 | 58.4 | 58.4 |
| ECOG PS 0 (vs 1-2) | 54.7 | 36.6 | 36.6 |
| Disease stage III-IV | 85.2 | 85.4 | 85.4 |
| FLIPI score of ≥3 | 60.9 | 35.4 | 35.4 |
| Prior CAR T therapy | 4.7 | 0.0 | 0.0 |
| Prior ASCT | 18.8 | 20.1 | 20.1 |
| POD24 | 52.3 | 26.8 | 26.8 |
| Refractory to last prior therapy | 68.8 | 46.4 | 46.4 |
| ≥3 prior LOTs (vs <3) | 63.3 | 57.6 | 57.6 |
| Bulky disease (>7 cm) | 11.7 | 22.1 | 22.1 |
ESS, effective sample size; PS, performance status.